Seminars in Oncology
Volume 34, Supplement 3 , Pages S4-S9, April 2007

A Pathologist’s Perspective on Emerging Genomic Tests for Breast Cancer

  • W. Fraser Symmans

      Affiliations

    • Dr Symmans owns stock in Nuvera Biosciences, Inc, Amgen Inc, Cell Therapeutics, and Isis Pharmaceuticals.
    • Corresponding Author InformationAddress reprint requests to W. Fraser Symmans, MD, Department of Pathology, Unit 85, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030

Department of Pathology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX.

Emerging molecular tests for breast cancer indicate how future progress in diagnostic pathology might guide patient care. However, the challenge will be to bring the best results from this exciting research into clinical use as accurate and reliable standardized tests that integrate into the diagnostic work-up.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(07)00070-X

doi:10.1053/j.seminoncol.2007.03.016

Seminars in Oncology
Volume 34, Supplement 3 , Pages S4-S9, April 2007

Article Tools

* Image Usage & Resolution